Search
Confirm
Close

ABOUT Viwit

With high-quality products and services, we continue to create more value for our customers, employees, shareholders and society, and contribute our talents and efforts to a healthier and better life

COMPANY PROFILE

    Viwit is an innovation driven biopharmaceutical and healthcare company with integrated research and development, production and marketing systems. Viwit is committed to building a platform for pharmaceutical innovation and commercialization, and establishing an ecosystem that serves the healthcare needs of the general public.

    Viwit was founded in 2006 as an R&D lab. With the collaborative efforts of the Viwit team, Viwit Pharmaceutical has evolved from developing chiral borane products to making drug intermediates, active pharmaceutical ingredients and biopharmaceutical products. Viwit has three integrated product research and development (R&D) centers, three cGMP production facilities (refer to history of Viwit), and marketing distribution systems in China, the United States, Canada, European Union and other regions. Viwit is continuously focusing and expanding its business scope and operations in the biopharmaceutical and healthcare industry.

PRODUCT INTRODUCTION

We are committed to developing into a global leading medical and health enterprise based on the overall competitive advantage of the industrial chain and based on technological innovation


HIGH DEMAND PRODUCTS

Adhering to customer demand, building core competitiveness, and striving to provide better and higher quality health products and services

Title

Levofloxacin Hydrochloride Injection 5ml: 0.5g

【Drug Name】 <br/>
&emsp;Generic Name: Levofloxacin Hydrochloride Injection<br/>
【Strength】 <br/>
&emsp;5ml: 0.5g<br/>
Title

Levofloxacin hydrochloride Injection 5ml: 0.3g

【Drug Name】 <br/>
&emsp;Generic Name: Levofloxacin Hydrochloride Injection<br/>
【Strength】 <br/>
&emsp;5ml: 0.3g<br/>
Title

Puerarin Injection 5ml: 0.25g

【Drug Name】 <br/>
&emsp;Generic Name: Puerarin Injection<br/>
【Strength】 <br/>
&emsp;5ml: 0.25g<br/>
Title

Puerarin Injection 8ml: 0.4g

【Drug Name】 <br/>
&emsp;Generic Name: Puerarin Injection<br/>
【Strength】 <br/>
&emsp;8ml: 0.4g<br/>

INNOVATION 

& collaboration platform 

CDMO

Viwit platform provides CDMO services of APIs and intermediates, oral solids (tablets, capsules), sterile liquid products (small volume injections-ampoules, vials, eye drops). 

威智医药

Project Collaboration

Viwit platform provides R&D project cooperation and commercialization, covering the entire pharma industrial value chain from finished drugs to APIs.              

威智医药
威智医药

Joint Venture

Provide marketing, fund raising and other resources.

In-/Out-Licensing

Viwit is dedicated to developing and providing innovative, valuable drugs to the general public and assisting our business partners to bring high-quality products to global markets.

威智医药

NEWS CENTER

Make due contribution to the development of the industry and society, and strive to become the pacesetter and pioneer of the industry.

2024

04 -09

On April 5, 2024, Viwit Pharmaceuticals' Levetiracetam Tablets received an Approval Letter (#078869) from the U.S. Food and Drug Administration (FDA), marking Viwit's first approved oral solid dosage in the United States.

2024

01 -26

On January 23, 2024, Viwit Pharmaceuticals received the "Notice of Approval of Application for Listing of Chemical APIs" issued by China National Medical Products Administration (NMPA) for its own proprietary active pharmaceutical ingredient (API) Mirabegron, developed independently. The issued registration number is Y20220000096, and the corresponding notice number is 2024YS00039.

2023

12 -22

Viwit Pharmaceuticals is pleased to announce the acquisition of the Drug Registration Certificate (Certificate No: 2023S01974) from the National Medical Products Administration (NMPA) for a proprietary finished dosage form, Vildagliptin tablet. This signifies the official approval of this product in the Chinese market.

2023

12 -19

On December 18, 2023, Viwit Pharmaceuticals received the "Drug Supplementary Application Approval Notice" (Notice No: 2023B06224) issued by the China National Medical Products Administration for a proprietary finished dosage form, Lidocaine Hydrochloride for Injection (5ml: 0.1g).

2023

12 -07

On November 30, 2023, Viwit Pharmaceuticals received the "Notice of Approval of Application for Listing of Chemical APIs" issued by National Medical Products Administration (NMPA) for its independently developed active pharmaceutical ingredient (API), Vildagliptin. The registration number is Y20210000619, and the notice number is 2023YS00803.